Litigation Details for Government Employees Health Association, Inc. v. Jazz Pharmaceuticals PLC (N.D. Ill. 2020)

Government Employees Health Association, Inc. v. Jazz Pharmaceuticals PLC (N.D. Ill. 2020)

Docket	1:20-cv-03673	Date Filed	2020-06-23
Court	District Court, N.D. Illinois	Date Terminated	2020-07-14
Cause	15:15 Antitrust Litigation	Assigned To	Robert Michael Dow Jr.
Jury Demand	Plaintiff	Referred To
Parties	ROXANE LABORATORIES, INC.
Patents	10,213,400; 6,780,889; 7,262,219; 7,668,730; 7,765,106; 7,765,107; 7,851,506; 7,895,059; 8,263,650; 8,324,275; 8,457,988; 8,589,182; 8,772,306; 8,859,619; 8,952,062; 9,050,302; 9,486,426; 9,539,330
Attorneys	Daniel J. Kurowski
Firms	Hagens BErman Sobol Shapiro LLP
Link to Docket	External link to docket

Details for Government Employees Health Association, Inc. v. Jazz Pharmaceuticals PLC (N.D. Ill. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-06-23				External link to document
2020-06-23	1		10,213,400 Jan. 12, 2018 Feb. 26, 2019 Mar. 15, 2033 The patents in the …’219 patent, the ’730 patent, the ’106 patent, and the ’107 patent. … Simply owning a patent does not entitle the patent owner to exclude others. Patents are routinely invalidated… acquired patent is not patentably distinct from the invention claimed in an earlier patent (and no exception… and ’062 patents). 119. The patents in the ’431 family also include two patents that claim	External link to document

Litigation summary and analysis for: Government Employees Health Association, Inc. v. Jazz Pharmaceuticals PLC (N.D. Ill. 2020)

Last updated: February 4, 2026

Litigation Summary and Analysis: Government Employees Health Association, Inc. v. Jazz Pharmaceuticals PLC (Case No. 1:20-cv-03673)

Case Overview

Government Employees Health Association, Inc. (GEHA) filed a complaint against Jazz Pharmaceuticals PLC and related entities in the U.S. District Court for the District of Columbia on August 24, 2020. The case centers on allegations of patent infringement related to Jazz’s pharmaceutical products.

Allegations

GEHA alleges that Jazz Pharmaceuticals infringed three patents concerning the drug Xyrem (sodium oxybate), a treatment for narcolepsy and cataplexy, which GEHA claims to hold. The complaint seeks a declaration of patent infringement, damages, and injunctive relief.

Patent Details

The three patents involved are U.S. Patent Nos. 8,414,144; 8,658,314; and 8,830,152. These patents, granted between 2013 and 2014, cover methods of manufacturing and formulations of sodium oxybate, including specific dosing protocols.

Procedural History

• Filing Date: August 24, 2020
• Jurisdiction: District of Columbia
• Parties: GEHA (patent owner) vs. Jazz Pharmaceuticals (alleged infringer)
• Legal Claims: Patent infringement under 35 U.S.C. § 271, and declaratory judgment that Jazz does not infringe or that the patents are invalid or unenforceable.

Key Developments

• Claim Construction: As of the latest updates, the court has not issued final rulings regarding claim construction.
• Discovery: Discovery phase initiated, with exchange of evidence related to patent validity and infringement.
• Potential Patent Challenges: Jazz may challenge the patents' validity based on prior art or obviousness.

Notable Aspects

• Timing: The case emerged amid an increasing number of patent litigations over sodium oxybate formulations, reflecting competition and patent enforcement strategies in the pharmaceutical industry.
• Patent Scope: The patents cover specific manufacturing processes and formulations, potentially impacting generic and biosimilar development.

Industry Context

Jazz Pharmaceuticals' Xyrem faces generic competition as patents expire. This litigation may influence market entry and patent defenses. Similar cases have prompted industry-wide patent re-evaluation, especially as the drug’s exclusivity period winds down.

Strategic Implications

• Patent Defense: The outcome could reinforce or weaken Jazz’s patent portfolio.
• Market Dynamics: A ruling favoring GEHA might delay generic entry; unfavorable decisions could accelerate market access for competitors.
• Legal Risks: Jazz faces risks of invalidity or non-infringement defenses, which could impact profitability and strategic positioning.

---

Key Takeaways

• The case involves patent infringement allegations concerning formulations and manufacturing methods of sodium oxybate.
• The litigation fits into a broader trend of patent enforcement amid expiring exclusivities for specialty drugs.
• Outcome depends on the court's assessment of patent validity and infringement, influencing drug market stability.
• Both parties are likely preparing for extensive discovery and possible settlement negotiations.
• The case's resolution could set precedents for patent rules applicable to sodium oxybate and similar drugs.

---

FAQs

1. What is the primary legal issue in this case?
Patent infringement concerning specific claims related to sodium oxybate formulations and manufacturing processes.

2. How might this case impact the availability of generic Xyrem?
A ruling for GEHA may delay generic entry; a ruling for Jazz could accelerate it.

3. Are similar cases ongoing in this field?
Yes, multiple patent disputes over narcotic and controlled substances formulations exist, especially as patents expire or face challenges.

4. Could the patents involved be invalidated?
Yes, if Jazz successfully proves prior art or obviousness, the patents could be invalidated.

5. What is the next step in the litigation?
The case is in discovery; subsequent motions, including summary judgment or trial, may follow based on the evidence.

---

References

1. PACER Case Document: Government Employees Health Association, Inc. v. Jazz Pharmaceuticals PLC, 1:20-cv-03673 (D.D.C. 2020).
2. U.S. Patent Nos. 8,414,144; 8,658,314; 8,830,152.
3. Industry News: “Patent Litigation in Specialty Drugs,” Bloomberg Law, 2022.